Drugs / EGT0001474
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00924053 | Jun → Jul 2009 | type 2 diabetes mellitus | Theracos | Completed | No outcome recorded |
| Phase 1 | NCT00854113 | Feb → Jul 2009 | — | Theracos | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGT0001474 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00854113 ↗ |
| Action | Inhibit | “EGT0001474 is an inhibitor of human sodium dependent glucose co-transporter II” NCT00854113 ↗ |
| Route | Oral | “Oral ascending doses given daily as capsules for up to 14 days” NCT00854113 ↗ |